Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

117.08 +0.34 (+0.29%)
Streaming Delayed Price Updated: 3:07 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
3 S&P 500 Stocks We Approach with Caution
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Intellectual Property Stocks
Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
From Gilead Sciences, Inc.
Via Business Wire
Breaking Down Gilead Sciences: 6 Analysts Share Their Views
 
Via Benzinga
Why Ionis Stock, Approaching A Six-Year High, Just Snagged A Price-Target Hike
The company is working toward a potential $5 billion sales peak for its partnered and unpartnered programs. 
Via Investor's Business Daily
Lupin Gains On FDA Nod For HIV Drug; Technicals Suggest Potential Upside Above ₹2,060
Via Stocktwits
Gilead Sciences Inc (NASDAQ:GILD) Presents a Compelling Case for Value Investors
Gilead Sciences (GILD) presents a strong value investing case with a low P/E ratio, high profitability, and solid cash flow, suggesting the stock may be undervalued. 
Via Chartmill
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
 
Via Benzinga
Gilead Sciences Settles Patent Litigations With Generic Drugmakers For Best-Selling HIV Drug: Analyst Cheers Longer Runway
The company stated that under the settlements, no generic entry is expected for Biktarvy in the United States before April 1, 2036. 
Via Stocktwits
Topics Intellectual Property
Gilead Reaches Settlement To Block Biktarvy Generics Until 2036
Gilead Sciences settled patent disputes with Lupin, Cipla, and Laurus, delaying U.S. generic entry of HIV drug Biktarvy until April 2036. 
Via Benzinga
Topics Intellectual Property
Telecom Stocks Rattled After Verizon Unexpectedly Names Dan Schulman New CEO
The appointment is effective immediately, replacing Hans Vestberg who has led Verizon since 2018. 
Via Investor's Business Daily
Gilead Scores A 'Solid Win' For Its Biggest Moneymaker; Shares Jump
The company is well known for its HIV treatment, Biktarvy. Biktarvy accounted for more than two-thirds of Gilead's HIV June-quarter sales. 
Via Investor's Business Daily
Topics Intellectual Property
Discover the top S&P500 movers in Monday's pre-market session.
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses. 
Via Chartmill
2 Surefire Dividend Stocks to Buy for the Long Haul
Both have crushed the market in 2025. 
Via The Motley Fool
Topics Economy Government Intellectual Property
Is Gilead Sciences Inc Gaining or Losing Market Support?
 
Via Benzinga
These 3 Pharma Stocks Are Rallying – And Still Trade Absurdly Cheap
Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount. 
Via Benzinga
Market Whales and Their Recent Bets on GILD Options
 
Via Benzinga
2 Nasdaq 100 Stocks on Our Watchlist and 1 We Brush Off
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing... 
Via StockStory
Topics Credit Cards
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by... 
Via MarketMinute
U.S. Government Teeters on Brink of Shutdown: Markets Brace for Uncertainty Amidst Data Blackout Fears
As the clock ticks towards the September 30, 2025, funding deadline, the United States federal government finds itself perilously close to another shutdown. Congressional leaders remain deadlocked on a... 
Via MarketMinute
Topics Bonds Economy Government
3 Unpopular Stocks We Approach with Caution
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps... 
Via StockStory
Gilead Foundation Grants $6.5 Million in Commitment to STEM Education
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Inc (NASDAQ:GILD) Shows Strong Technical Setup for Potential Breakout
Gilead Sciences (GILD) shows strong technicals with a top rating of 9. It's forming a high-quality consolidation pattern, suggesting a potential breakout above $117.42. 
Via Chartmill
If You Invested $100 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today
 
Via Benzinga
3 Profitable Stocks We’re Skeptical Of
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
Cumberland First in Families to Host 2nd Annual Mister & Miss FIFNC Pageant
Via Get News
What Analysts Are Saying About Gilead Sciences Stock
 
Via Benzinga
3 Reasons GILD is Risky and 1 Stock to Buy Instead
Gilead Sciences has been treading water for the past six months, holding steady at $112.78. The stock also fell short of the S&P 500’s 16.5% gain during that period. 
Via StockStory
Topics Government Stocks
U.S. Economy Braces for Significant Slowdown: Leading Indicators Signal Weakening, Not Yet Recession
The U.S. economy finds itself at a critical juncture, as signals from The Conference Board's Leading Economic Index (LEI) point toward a sustained period of economic weakening. While the LEI's... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
These S&P500 stocks are gapping in today's session
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Monday. Stay informed about the latest market trends. 
Via Chartmill
Biotech Sector May Flip to Market Leader by Year-End
As rate cuts loom and after years of lagging, the biotech sector is showing signs of life, with IBB outpacing the benchmark S&P 500 on the quarter. 
Via MarketBeat
Topics ETFs Economy Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.